|
Post by mnkdfann on Apr 21, 2017 11:51:58 GMT -5
Stock has been trading this week as to we are going to hear some very negative news in the next few days ... My gentleman's bet is on AH news.
|
|
|
Volume too
Apr 21, 2017 12:04:54 GMT -5
via mobile
Post by saxcmann on Apr 21, 2017 12:04:54 GMT -5
Stock has been trading this week as to we are going to hear some very negative news in the next few days ... My gentleman's bet is on AH news. My bet is no news. What negative news could come?...too early for bankruptcy news?
|
|
|
Post by mnkdfann on Apr 21, 2017 12:21:36 GMT -5
My gentleman's bet is on AH news. My bet is no news. What negative news could come?...too early for bankruptcy news? I have to admit, you have a point. I can't really imagine what negative news there could be. Well, that's why it was only a gentleman's bet.
|
|
|
Post by seanismorris on Apr 21, 2017 12:47:30 GMT -5
I haven't heard any news that justifies the drop today, and I don't expect to hear anything after today's close.
Unfortunately, there is nothing to prop up MNKD's stock price in the face of continued dilution.
We have to be getting close to investors being hope free, which would normally be the time to buy. Unfortunately I've been hope free for quite a while... unless scripts take off the company and stock will continue it's death spiral.
For those that want Matt to say something, I'm not sure what you want him to say. They obviously don't have any answers and you don't really want the truth.
Doctors don't have any reason to prescribe Afrezza. Afrezza is a niche product that won't bring in enough money to keep the company afloat.
While I do think Afrezza is better than the Alternatives if taken right. It's also too easy to take wrong, and management has been lying about that from the beginning.
|
|
|
Post by mockingjay on Apr 21, 2017 12:57:17 GMT -5
I think Deerfield is dumping their shares
|
|
|
Post by sellhighdrinklow on Apr 21, 2017 13:17:09 GMT -5
I haven't heard any news that justifies the drop today, and I don't expect to hear anything after today's close. Unfortunately, there is nothing to prop up MNKD's stock price in the face of continued dilution. We have to be getting close to investors being hope free, which would normally be the time to buy. Unfortunately I've been hope free for quite a while... unless scripts take off the company and stock will continue it's death spiral. For those that want Matt to say something, I'm not sure what you want him to say. They obviously don't have any answers and you don't really want the truth. Doctors don't have any reason to prescribe Afrezza. Afrezza is a niche product that won't bring in enough money to keep the company afloat. While I do think Afrezza is better than the Alternatives if taken right. It's also too easy to take wrong, and management has been lying about that from the beginning. Please explain how it is too easy to take (Afrezza) wrong. I've been taking Afrezza for two years and your statement is nothing but FUD. Fact.
|
|
|
Post by peppy on Apr 21, 2017 13:19:15 GMT -5
|
|
|
Volume too
Apr 21, 2017 13:33:45 GMT -5
via mobile
Post by lakers on Apr 21, 2017 13:33:45 GMT -5
I think Deerfield is dumping their shares Yes. Deerfield indeed. 30M shares presplit.
|
|
|
Post by lennymnkd on Apr 21, 2017 14:02:27 GMT -5
Deerfield! And what does it mean , going forward ?
|
|
|
Post by mnkdfann on Apr 21, 2017 14:05:55 GMT -5
Broke 0.89.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 21, 2017 14:10:37 GMT -5
NO, your statement is FUD. Just because it works for you does not mean it works for everyone. You touting away at its life changing benefits has not helped investors either. Clearly, there have been a ton PWD who struggled with Afrezza because the retention rate is terrible. Clearly, MNKD has struggled to guide these PWD to successful use Afrezza or the retention rate would be better. You have to wonder about people's intentions when they label criticism of Afrezza as FUD when it has been a colossal failure.
|
|
|
Post by peppy on Apr 21, 2017 14:26:08 GMT -5
NO, your statement is FUD. Just because it works for you does not mean it works for everyone. You touting away at its life changing benefits has not helped investors either. Clearly, there have been a ton PWD who struggled with Afrezza because the retention rate is terrible. Clearly, MNKD has struggled to guide these PWD to successful use Afrezza or the retention rate would be better. You have to wonder about people's intentions when they label criticism of Afrezza as FUD when it has been a colossal failure. The physicians did not know how to prescribe. I think it is that insurance didn't cover and then physicians not prescribing and those physicians that did prescribe, did not know how to titrate. Diabetics go through hell trying to learn insulin. www.slideshare.net/StephenPonder/sugar-surfing-with-a-cgm-copyright-tlc-advanced-diabetes-retreat-april-26-2014
Not that many people have continuous glucose monitors. The Afrezza users were working blind. They did not know what to expect. Those 12 people you say are on twitter, compound counted 70 between twitter and instagram. These people are happy. They figured it out.
The insulin is wonderful. Pharma is huge, MNKD is small. Trials so cost prohibitive.
Perhaps the story is different than the one you write.
|
|
|
Post by fanz8967 on Apr 21, 2017 14:40:09 GMT -5
NO, your statement is FUD. Just because it works for you does not mean it works for everyone. You touting away at its life changing benefits has not helped investors either. Clearly, there have been a ton PWD who struggled with Afrezza because the retention rate is terrible. Clearly, MNKD has struggled to guide these PWD to successful use Afrezza or the retention rate would be better. You have to wonder about people's intentions when they label criticism of Afrezza as FUD when it has been a colossal failure. The physicians did not know how to prescribe. I think it is that insurance didn't cover and then physicians not prescribing and those physicians that did prescribe, did not know how to titrate. Diabetes go through hell trying to learn insulin. www.slideshare.net/StephenPonder/sugar-surfing-with-a-cgm-copyright-tlc-advanced-diabetes-retreat-april-26-2014
Not that many people have continuous glucose monitors. The Afrezza users were working blind. They did not know what to expect. Those 12 people you say are on twitter, compound counted 70 between twitter and instagram. These people are happy. They figured it out.
The insulin is wonderful. Pharma is huge, MNKD is small. Trials so cost prohibitive.
Perhaps the story is different than the one you write.
All problems that required a lot of resources to be addressed, very early on. Matt was out of his league. He was clearly not qualified to launch this nor did he have the cash or people on the ground to educate and promote. Sorry, but his arrogance, greed, and refusal to seek out a new BP partner cost investors collective billions.
|
|
|
Post by peppy on Apr 21, 2017 15:04:20 GMT -5
4,349,413 real time shares traded. summary quote showing 5,569,192 shares. www.nasdaq.com/symbol/mnkd/real-time
(ii) exchange $1 million principal amount under the Tranche B Notes for 869,565 shares of the Company’s common stock (the “Tranche B Exchange Shares”) and
(iii) exchange $5 million principal amount under the Amended and Restated 9.75% Senior Convertible Notes due 2019 held by Deerfield (the “Tranche 1 Notes”) for 4,347,826 shares of the Company’s common stock (together with the “Tranche B Exchange Shares”, the “Exchange Shares”).
|
|
|
Post by seanismorris on Apr 21, 2017 15:06:55 GMT -5
Congratulations! But it's not FUD.
There is only one FACT here. Afrezza's scripts aren't increasing. While we all hope that will change. The reality is what it is...
The new sales force hasn't had a meaningful impact on scripts. Why? We can't blame it all on lack of insurance coverage. We can't blame it all on price, MannKind is offering discounts, etc.
Afrezza is easy to take... just inhale. So, what's the problem? There has to be a problem, because there is obviously been something that hasn't been addressed or can't be addressed.
What's left? Dosing. And, Doctor reluctance to have patients try Afrezza.
Afrezza is a product that requires patients to actively monitor their disease and dose with Afrezza appropriately to stay within optimal levels. This is obviously creating user adoption issues, and docs aren't willing to give patients that kind of responsibility. Doc's want to be able to say "take one pill, or two pills" or "one shot" etc.
So in the real world patients aren't taking enough Afrezza, or compensating (upwards) when it doesn't work as expected.
Docs can only hold patients hands so much.
-----
Let's put it this way. I'm an IT guy. It's easy... everything you need to know to fix almost any problem is out there on the Internet. Still users don't want to figure it out, even if the answer is 30sec. away on Google. I get a lot of calls...
So back to Afrezza, Docs are reluctant to prescribe Afrezza because they will be getting calls all day long. It doesn't matter if it's easy it's still wasting the docs time. If Afrezza had the "superior" label maybe it would be worth it. But it doesn't, and marginally improved outcomes isn't enough to justify the hassle.
Am I reaching? Yes. Am I putting words in docs mouths? Yes Am I making conclusions based on to little information? Yes
Has anyone come up with a better explanation? No
My conclusion is Afrezza is a niche product, and that's really bad for MannKinds future.
Take a look at my posting history. I was as optimistic as anyone and have never been Short MNKD. What benefit would I have for spreading FUD. None.
If I needed to use Afrezza I expect I'd have a "superior" outcome. I'm a "figure it out" kind of guy... I wouldn't really need my doc. But docs aren't prescribing for me. They're going to assume they're prescribing for the lowest common denominator. So, unless the patient demands Afrezza, they're going to look elsewhere.
I hope I'm wrong, but everything I've seen says I'm right.
|
|